Trial record 3 of 26 for:    Ustekinumab | Open Studies

Exploratory Study on Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With Type 1 Diabetes Mellitus

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by Jewish General Hospital
Sponsor:
Information provided by (Responsible Party):
Lawrence Rosenberg, Jewish General Hospital
ClinicalTrials.gov Identifier:
NCT02204397
First received: July 28, 2014
Last updated: June 28, 2016
Last verified: June 2016
  Purpose
A proof-of-concept for safety and preliminary clinical efficacy of a combined regimen of INGAP-P for β-cell regeneration and ustekinumab for IL-12-23 autoimmune modulation in patients with established T1DM.

Condition Intervention Phase
Type 1 Diabetes Mellitus
Drug: INGAP Peptide, Ustekinumab
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single-center, Open-Label, Exploratory Study to Assess the Tolerability and Safety of the Addition of Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With Type 1 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Jewish General Hospital:

Primary Outcome Measures:
  • Safety and tolerability [ Time Frame: 6 months ]
    The tolerability of injections and general safety will be assessed on the basis of patient recorded diaries, assessments of cutaneous injection sites during clinic visits, clinical observations, severity of AEs recorded by the Medical Dictionary for Regulatory Activities (MedDRA), measurement of vital signs, physical examinations, electrocardiograms (ECGs), and clinical laboratory evaluations.


Secondary Outcome Measures:
  • Composite C-Peptide efficacy according to specific parameters [ Time Frame: 6 months ]

    Composite secondary objectives of this study are to generate preliminary data on the efficacy of INGAP-P and ustekinumab in adult patients with established T1DM, specifically by change from baseline to Week 12-13 in:

    • Maximal C-peptide (Cmax) during mixed meal test (MMT) and glucagon stimulated test (GST);
    • C-peptide release (AUC) during MMT and GST;
    • Fasting C-peptide;
    • Fasting glucose (before breakfast and after at least 8 hours of fasting);
    • Longer term glycemic control as reflected by glycosylated hemoglobin (HbA1c)


Estimated Enrollment: 5
Study Start Date: November 2015
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: INGAP Peptide, Ustekinumab
INGAP Peptide, Ustekinumab subcutaneous
Drug: INGAP Peptide, Ustekinumab
Other Names:
  • INGAP Peptide
  • Ustekinumab (Stelara)

Detailed Description:

The primary objective of this study is to assess the safety and tolerability of 12 weeks of subcutaneous (SC) daily administration of INGAP-P (600 mg SC once a day in three separate injection sites) with ustekinumab (two single injections of 45 mg SC, one as pretreatment two weeks before INGAP-P treatment begins and the second one after 2 weeks of INGAP-P treatment) in adult patients with established type 1 diabetes mellitus (T1DM). Safety will be evaluated by assessing local tolerability, recording incidence of hypoglycemia, performing safety laboratory measures at frequent intervals, and following subjects very closely for any adverse events (AEs).

Secondary objectives of this study are to generate preliminary data on the efficacy of INGAP-P and ustekinumab in adult patients with established T1DM, specifically by change from baseline to Week 12 in: 1) Maximal C-peptide (Cmax) during mixed meal test (MMT) and glucagon stimulated test (GST); 2) C-peptide release (AUC) during MMT and GST; 3) Fasting C-peptide; 4) Fasting glucose (before breakfast and after at least 8 hours of fasting); 5) Longer term glycemic control as reflected by glycosylated hemoglobin (HbA1c) and 1,5-anhydroglucitol (1,5-AG); and, 6) Total daily insulin dose relative to body weight.

  Eligibility

Ages Eligible for Study:   19 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female patients between the ages of 19 and 40 years old, inclusive, with a history of T1DM for >2 years and ≤20 years;
  2. Female patients will not be breast-feeding during the study or within at least seven days after the study is completed;
  3. Receiving multiple daily insulin injections or insulin pump therapy for >2 years;
  4. Body mass index (BMI) ≤32 kg/m2 and total body weight <100 kg;
  5. HbA1c ≤8.2%,
  6. Fasting C-peptide levels >0.1 ng/mL and <1.0 ng/mL;
  7. CBC and platelet counts must be within normal limits, and specifically, the total absolute neutrophil count must not be <1500/μL;
  8. Willing to sign the study informed consent document;
  9. In good general health with no infections, active tuberculosis (TB), late severe complications, or concomitant medical conditions that would influence the outcome of the trial, at the discretion of the Investigator and the Sponsor;
  10. If treated with angiotensin-converting enzymes/angiotensin II receptor blockers (ACE/ARB), the doses should be unchanged for a month prior to enrollment;
  11. Females of child bearing potential must have a negative urine pregnancy test on Day 0 prior to dispensing drug and should additionally fulfill one of the following criteria:

    • Willing to use oral, implantable, transdermal, or injectable contraceptives for 21 days prior to the first dose and until 28 days after the last dose; or,
    • Willing to use another reliable means of contraception approved by the Investigator (intrauterine device, female condom, diaphragm with spermicide, cervical cap, use of condom by sexual partner, or a sterile sexual partner) from Screening until after the last blood sample (at Week 16).

Exclusion Criteria:

  1. Total daily insulin dosage exceeding 1.0 U/kg/day or a change in total daily insulin dose level of more than 50% (increase or decrease) within the past 3 months;
  2. Treatment with any diabetes medication other than insulin;
  3. A score of 4 or more restricted responses on the Clarke Hypoglycemia Awareness Survey;
  4. Systolic or diastolic blood pressure >180 mmHg or >110 mmHg, respectively;
  5. Clinical worsening of retinopathy or neuropathy in the previous 3 months;
  6. Clinical worsening of nephropathy in the previous 3 months, or serum creatinine exceeding 2.0 mg/dL,;
  7. History or presence of acute or chronic pancreatitis, including a serum amylase level >1.5 times the upper limit of normal (ULN) or a serum lipase level >2 times ULN;
  8. Active infections at screening and during the study;
  9. History of asthma;
  10. History of TB;
  11. Administration of bacille Calmette-Guérin (BCG) vaccine for TB during the one year before the Screening Visit or one year after the last dose of ustekinumab;
  12. A history or presence of any illness, disease, or condition (including cancer) that could impact patient safety or evaluability of drug effect, in the Investigator‟s opinion;
  13. An episode of severe hypoglycemia (change in mental status requiring assistance) during the previous 30 days;
  14. An episode of acute glycemic decompensation with associated hyperosmolar non-ketotic state or diabetic ketoacidosis during the past 6 months;
  15. A serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin level >2 times ULN;
  16. Received any investigational product within 30 days of admission into this study or had any prior or existing exposure to INGAP-P, glucagon-like peptides (GLP-1, GLP-2, or analogs), ustekinumab, or TNF blocking agents (Patients that participated in the placebo group of previous INGAP-P study E-201 are not excluded from this study.);
  17. Known hypersensitivity to INGAP-P or any excipient used in the formulation;
  18. Known hypersensitivity to ustekinumab or any components of the product;
  19. Concurrent or planned participation in any other clinical study during the conduct of this study;
  20. Positive urine test for cocaine, opiates, amphetamines, or cannabinoids;
  21. Inability to fill out and maintain a daily diary during the screening period prior to dosing;
  22. Human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C seropositivity in blood sample taken during screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02204397

Locations
Canada, Quebec
Montreal General Hospital Recruiting
Montreal, Quebec, Canada, H3G 1A4
Contact: George M. Tsoukas, MD    514 934-8017    g.tsoukas@gmail.com   
Contact: Louise Ullyatt, RN    514-934-1934 ext 42115    lullyatt@gmail.com   
Principal Investigator: George Tsoukas, MD         
Sponsors and Collaborators
Jewish General Hospital
Investigators
Principal Investigator: George Tsoukas, MD Department of Endocrinology and Metabolism, Montreal General Hospital
  More Information

Responsible Party: Lawrence Rosenberg, Executive Director, Jewish General Hospital
ClinicalTrials.gov Identifier: NCT02204397     History of Changes
Other Study ID Numbers: JewishGH 
Study First Received: July 28, 2014
Last Updated: June 28, 2016

Keywords provided by Jewish General Hospital:
Type 1 Diabetes mellitus
INGAP
Ustekinumab

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Ustekinumab
Dermatologic Agents

ClinicalTrials.gov processed this record on January 19, 2017